As shown in Figure 5A, we found that combined treatment with eupafolin and TRAIL enhanced the sub-G1 population and PARP cleavage in U251MG (glioma cells) and DU145 cells (prostate cancer cells). Here, TNFSF10 is linked to prostate cancer.